

Public Statement on the Final Code of Practice
Over the past year, Pour Demain has worked closely with the AI Office, the independent expert Chairs and Vice Chairs, and other plenary...
11. Juli


Priorities to Uphold European Biosecurity in 2025
A Joint Briefing by Pandemic Action Network, RAND Europe, IBBIS, Centre for Future Generations and Pour Demain The European Union (EU) is...
10. Juli


The Code of Practice: Pour Demain’s contributions to EU guidelines for general-purpose AI models
Illustration generated by Gamma The final draft of the EU’s Code of Practice  for general-purpose AI (GPAI) models is expected to be...
26. Juni


Securing Europe's Biotech Future: Our Joint Contribution to the EU Biotech Act
Pour Demain submitted a joint contribution with 14 co-signees to the European Commission’s Call for Evidence on the EU Biotech Act, alongside colleagues from academia, industry, and civil society.
Our recommendations show how embedding biosecurity into EU biotech governance can strengthen innovation, bolster strategic autonomy, and build a high-trust bioeconomy.
18. Juni


Auditing Aetheria: A story of a secure remote third-party GPAI audit
The following is a fictional short-story about a remote third-party general purpose AI audit, occurring within the EU in the year 2028....
30. Mai


Resilientes Europa: Clevere Investitionen in lebensrettende medizinische Gegenmaßnahmen und Bevorratung
Pour Demain hat in Zusammenarbeit mit Blueprint Biosecurity und RAND Europe Feedback zu zwei wichtigen EU-Konsultationen eingereicht: zur...
8. Mai


Can the EU’s Dual Strategy of Regulation and Investment Redefine AI Leadership?
The following is an excerpt of an op-ed published by Pour Demain in Tech Policy Press . The article provides nuance to the innovation vs...
23. Apr.


Biosecurity in the EU's Internal Security Strategy?
Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...
17. März


Brief: Biosecurity & Nucleic Acid Synthesis
Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...
5. Dez. 2024


Nächste Schritte in der KI-Gouvernanz: Die Bedeutung umfassender GPAI-Modellevaluierungen
Während sich die Europäische Union auf die Umsetzung des KI-Gesetzes vorbereitet, ist die Sicherstellung robuster Evaluierungsmethoden...
7. Nov. 2024